Author: @admin

Post

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020

Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020 Oxford, UK, and Cambridge, MA, US, June 2, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today reports its financial results and provides an update on its operational conditions...

Post

SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales

SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales Appointment of seasoned women’s health marketing executive is a key step in the transition to a fully-integrated drug development and commercial company with initial focus on vaginal yeast infection JERSEY CITY, N.J., June...

Post

Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 29, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement with several healthcare-focused institutional investors, including Fidelity Management & Research...

Post

Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe  CHMP opinion supported by robust safety and efficacy data from two global pivotal Phase 3 trials of XENLETA  European Commission decision anticipated in the second half of 2020 DUBLIN,...

Post

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on...

Post

Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million

Financing advances clinical development of two innovative product candidates for the treatment of life-threatening diseases affecting patients with compromised immune systems   SAN DIEGO – May 19, 2020 – Amplyx Pharmaceuticals, a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that it has closed a...

Post

Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix

Completes Enrollment of Phase 2 Candida Trial Treats First Patients in Phase 2 Trials in Aspergillus and Candida auris Infections   SAN DIEGO – May 19, 2020 – Amplyx Pharmaceuticals, a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that it has advanced development of...

Post

National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS community-acquired pneumonia (CAP) guidelines DUBLIN, Ireland, May 18, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...

Post

Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates

-Cash runway extended into the fourth quarter of 2020 through judicious resource management- –XENLETA managed care coverage and patient reimbursement continues to strengthen- -Potential value-creating life cycle management for XENLETA initiated via non-dilutive support- -Conference call today at 4:30 p.m. Eastern Time– DUBLIN, Ireland, May 11, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV),...

Post

SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update

SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update In April, SCYNEXIS announced positive top-line results from the Phase 3 VANISH-306 study evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as vaginal yeast infection. NDA submission for this indication is...